Stem Cell Therapy for
COPD & Inflammatory Lung Disease
According to the World Health Organization (WHO), almost 3.23 million deaths were recorded in 2019 due to Chronic Obstructive Pulmonary Disease (COPD). Many allergic or harmful agents in the environment cause damage to the lungs.
Advanced Pulmonary Matrix
Targeted Respiratory Repair
Stem cell therapy aims to reduce chronic airway inflammation and support repair of damaged lung tissue, helping patients breathe easier and regain everyday function.
Available treatments are not fully curing the disease, but they can relieve symptoms. Prior treatments include medicines, lifestyle changes, exercise, and oxygen administration.
Emphysema, bronchitis, asthma, and bronchiectasis are common diseases that are related to the general term of chronic obstructive pulmonary disease.
Stem Cell transplantation seems promising in treating COPD and other diseases.
What Causes Chronic Obstructive Pulmonary Disease?
These days, cigarettes are the leading cause of obstruction in the lungs. The tar in cigarettes blocks blood vessels in the lungs, making it difficult to pump oxygen through blood. Other than that, chemical allergens, passive smoking, dust particles, pollens, age-related issues, and genetic disorders are the leading causes of chronic obstructive pulmonary disease.
Emphysema (Destruction of alveoli cells) and bronchitis (Bronchial tubes in the lungs inflamed) are the primary diseases that cause inflammation in the lungs. Bronchi is the main passageway of air in the body. These tubes are further divided into alveolar sacs and bronchioles. At this end, we have a blood-breath barrier, which gets disturbed due to COPD.
Bronchitis is the inflammation in this passageway, causing a narrow way of air in the body. Due to the constriction in these tubes, mucus builds up in the cells. Meanwhile, emphysema makes it challenging to outflow air from the body.
In Bronchitis, the lungs suffer from the loss of elasticity in the windpipe and sacs. These alveolar sacs and c-shaped cartilage in the airway cannot exhale air. This is how some air remains trapped in the body, leading to chronic diseases.
Signs & Symptoms of COPD that are Treated at Stem Cells Bio Clinic
Can Stem Cell Improve Symptoms of COPD?
In some clinical trials, it has been noticed that MSCs can lower immune response to allergies and other factors. They can also reduce lung inflammation and repair and replace alveolar cells. Researchers and medical professionals believe these building cells can signal general growth factors in the body to start the rebuilding process. Also, extracellular matrix (Exosomes) and peptide proteins can aid this mechanism. Exosomes are rebuilding agents other than stem cells. Their recovery rate is 3 times of stem cells. In clinical trials on different species and humans, MSCs were safe procedures for COPD. They didn’t show any noticeable transformation or reaction after their therapeutic procedure.
In the first phase of clinical trials, MSCs reduced the expression of CD31 (gene protein), and endothelial markers were found in the patient’s lungs suffering from emphysema. In some cases, inflammatory marker C protein also reduced their expression. These results showed that MSCs can help in COPD. According to ClinicalTrials.gov, 23 trials have shown their efficiency and long-term positive results on patients.
Severe inflammation in the lungs and windpipe are the main symptoms of COPD. Mesenchymal Stem Cells (MSCs) can improve overall lung functions by reducing inflammation. Stem cells can improve the overall health of the lungs, and modifying the lifestyle can cure COPD patients.
Benefits of Mesenchymal Stem Cells from Human Umbilical Cord
This reduces the patient’s recovery time; no invasive method is applied to extract stem cells.
They can be processed multiple times.
They are more tolerant of environmental toxins.
They can adapt more quickly than other cells.
MSCs can regenerate more efficiently.
Their proliferative (Replicating) activity is higher.
They are immunosuppressive and immunomodulatory, so there is less rejection rate from Human Leukocyte Antigen (HLA).
They are present more in number in the body than marrow stem cells and adipose stem cells.
They are resistant to the aging process.
What is the Special Protocol in Stem Cells Bio Clinic for Treating COPD?
The Stem Cells Bio Clinic recommends using MSCs over other stem cells for the best of patients. These cells are obtained from newborn babies with the proper consent of parents. MSCs are easy to differentiate and inject into the targeted body. Treatment included at stem cells bio clinic are:
These specialized therapies are applied at Stem Cells Bio Clinic, catering to patient’s different needs after consulting with our specialists in Stem Cells Bio Clinic.
How are Stem Cells Collected?
At Stem Cells Bio Clinic, we follow ethical guidelines allowed by the World Health Organization (WHO). We collect MSCs from the placenta of newborn babies. We collect these cells with the proper consent of parents. We only use exclusive umbilical mesenchymal stem cells.
How are Stem Cells Managed?
Our professional and specialized nursing staff extracts stem cells from intravenous and intra-pulmonary routes. For convenience, an intravenous route is preferred.
Scientific References:
Glassberg, M. K., Csete, I., Simonet, E., & Elliot, S. J. (2021). Stem Cell Therapy for COPD: Hope and Exploitation. Chest, 160(4), 1271–1281. https://doi.org/10.1016/j.chest.2021.04.020
Cheng, et al. Mesenchymal Stem Cell Administration in Patients with Chronic Obstructive Pulmonary Disease: State of the Science. Stem Cells International, vol. 2017, Article ID 8916570, 14 pages. https://doi.org/10.1155/2017/8916570
Kokturk, N., Yıldırım, F., Gülhan, P. Y., & Oh, Y. M. (2018). Stem cell therapy in chronic obstructive pulmonary disease. How far is it to the clinic? American Journal of Stem Cells, 7(3), 56–71. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146161/
Antoniou, K. M., Karagiannis, K., Tsitoura, E., Bibaki, E., Lasithiotaki, I., Proklou, A., et al., & Tzanakis, N. (2018). Clinical applications of mesenchymal stem cells in chronic lung diseases (Review). Biomedical Reports, 8, 314–318. https://doi.org/10.3892/br.2018.1067
Sun, Z., Li, F., Zhou, X., Chung, K. F., Wang, W., & Wang, J. (2018). Stem cell therapies for chronic obstructive pulmonary disease: Current status of pre-clinical studies and clinical trials. Journal of Thoracic Disease, 10(2), 1084–1098. https://doi.org/10.21037/jtd.2018.01.46
Weiss, D. J., Casaburi, R., Flannery, R., LeRoux-Williams, M., & Tashkin, D. P. (2013). A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest, 143, 1590–1598.